SCM
ARTV

Sterling Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Sterling Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$698 Buy
+72
New +$656 ﹤0.01% 3190
2025
Q2 		– Sell
-158
Closed -$474 – 3429
2025
Q1 		$474 Sell
158
-58
-27% -$313 ﹤0.01% 2964
2024
Q4 		$2.18K Buy
216
+185
+597% +$2.22K ﹤0.01% 2764
2024
Q3 		$479 Buy
+31
New +$359 ﹤0.01% 2891

Other funds holding ARTV

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Sterling Capital Management's ARTV Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 72 shares worth $698. The stake represents ﹤0.01% of the portfolio and ranks #3190 among its holdings. This is a return to the name: Sterling Capital Management previously reported a position in ARTV as recently as Q1 2025.

Sterling Capital Management first reported a position in ARTV in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.18K in Q4 2024. 5 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Sterling Capital Management held 72 shares of Artiva Biotherapeutics worth $698 as of Q2 2026.
  • Artiva Biotherapeutics was a new Sterling Capital Management position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3190 holding.
  • Sterling Capital Management first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 4 quarters since.
  • Sterling Capital Management's Artiva Biotherapeutics position peaked at $2.18K in Q4 2024.
  • 5 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.